Short term future of PAB, page-45

You can see this happening all across the industry, early-stage biotechs have seemingly lost favour with the crowds. Previously where a sniff of good news could send a biotech price multiples higher, now they seem to sit on the fence neither gaining nor losing much ground. In my opinion this is a reflection of caution and patience. The same way holders need to be patient for the big news, prospective investors seem to be more patient before buying in.

I've got a few watchlists across different biotech fields and most that are pre-commercialisation are in a similar boat, "price sensitive" announcements and little movement to show for it. I think these days it's better to track announcements to confirm they're on track towards major milestones, rather than looking to the share price.

Based on the recent announcements, I believe PAB is on track, and therefore I'm happy to hold and wait. What it will take to kick the share price into action, and when it will drop is anyone's guess.